J.P. Morgan analyst Anupam Rama has maintained their bullish stance on ANAB stock, giving a Buy rating on September 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anupam Rama has given his Buy rating due to a combination of factors surrounding AnaptysBio’s potential in the ulcerative colitis market. The upcoming 12-week phase 2 results for rosnilimab, a treatment for ulcerative colitis, present a promising opportunity as the current market valuation does not fully reflect its potential. This creates an attractive risk-reward scenario for investors.
Furthermore, the company anticipates that positive data from the 12-week study could significantly increase the stock’s value, with further updates in 2026 potentially adding more value. AnaptysBio’s existing revenue streams, such as Jemperli royalties, also support the stock’s valuation. The analyst highlights the absence of major safety concerns in the ongoing studies, which bolsters confidence in the drug’s development and potential market success.
In another report released on September 16, Leerink Partners also maintained a Buy rating on the stock with a $0.00 price target.